BRAIN: 18F-flortaucipir PET compared to autopsies in Alzheimer's disease and other neurodegenerative diseases

Few studies have assessed the relationship between live 18F-flortaucipir PET and posthumous pathology.
we tried to compare the 18F-flortaucipir PET with neuropathology in a range of patients with a wide range of neurodegenerative diseases.
included 20 patients with an average age of 61 years (range 34-76) and a 30-month (4 to 59 months) between eight female PET and autopsies.
8 patients had primary Alzheimer's pathology, 9 had non-Alzheimer's disease (progressive nuclear paralytic paralysis, cortical substrate degeneration, silver-like granules disease and frontal temporal lobe degeneration with MAPT mutations), and 3 had non τ
using the lower cer cerebrocephaly reference to create an 80-100-minute 18F-fancy PET standardized intake ratio (SUVR) image.
calculates the average of SURVs for sexual nuclear paralysis, cortical substrate degeneration, and the entanglement of neurogenic fibers of interest in the Braak period region, and compares these values with SUVR (used as a tau negative standard) derived from young non-autopsy, cognitive normal control.
, the combination of tau-positive and tau-negative non-Alzheimer's disease with post-mortem tau pathology is unreliable.
18F-flortaucipir SUVR in the subsurgery region was higher than the control group in patients with carried-on nuclear paralysis and cortical substrate degeneration confirmed by autopsies, but was similar to measurements of Alzheimer's disease and tau-negative neurodegenerative lesions.
18F-flortaucipir SUVR images of areas of interest to the Braak period can reliably detect the pathology of late-stage Alzheimer's disease (Braak VI).
, however, there was no increase in tracer intake in these areas in braak patients (Braak I-IV) who were older than young tau-negative controls.
, the comparison between PET and autopsy confirms that 18F-flortaucipir PET is a reliable biomarker of Braak tau pathology in the advanced stages of Alzheimer's disease.
tracer is not reliable for non-Alzheimer's disease, or it may not detect neurogenic fibrous entanglement pathology in the early Braak period.
original source: David Soleimani-Meigooni, Leonardo Iaccarino, Renaud La Joie, MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Mets Medical and are not authorized to reproduce by any media, website or individual, and are authorized to be reproduced with the words "Source: Met Medical".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here